Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,391 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Pill Clear all

Conditions: Congestive Heart Failure
Interventions: carvedilol controlled release, carvedilol immediate release; Drug
Lead sponsor: CTI-1, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 75
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more

Conditions: Nocturia
Interventions: fedovapagon 1 mg, fedovapagon 2 mg, fedovapagon 4 mg, Placebo ( sugar pill); Drug
Lead sponsor: Vantia Ltd; Industry
Eligibility: 55 Years and older · Male only
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 56
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 53 more

Conditions: Gulf War Illness
Interventions: Placebo, Visbiome, VSL#3; Drug
Lead sponsor: Ashok Tuteja; Federal
Eligibility: 35 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Schizophrenia
Interventions: Clozapine augmented with atomoxetine up to 40 mg or placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission
Interventions: Compliance Monitoring, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Questionnaire Administration, Study of Socioeconomic and Demographic Variables; Behavioral · Other · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2020
U.S. locations: 124
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 105 more

Conditions: Mild Traumatic Brain Injury
Interventions: Tolcapone, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Systemic Inflammation, Aging
Interventions: Fermented Papaya Preparation (FPP), Sugar Pill; Drug
Lead sponsor: University of Florida; Other
Eligibility: 70 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cervical Dystonia
Interventions: Ingrezza Pill; Drug
Lead sponsor: The Orthopedic Foundation; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Albany, Ohio

Conditions: Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Orthostatic Hypotension
Interventions: Droxidopa, Midodrine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bipolar Disorder
Interventions: Placebo, Metformin; Drug
Lead sponsor: Cynthia Calkin; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Aging
Interventions: Sirolimus; Drug
Lead sponsor: Irina Timofte; Other
Eligibility: 65 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Aging
Interventions: Rapamycin, Everolimus, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 65 Years to 90 Years
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Osteoblast, Adipocytes, Bone Density, Osteocalcin, Adiponectin, Mesenchymal Stem Cells
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Major Depressive Disorder
Interventions: Duloxetine; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 40 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Lung Diseases, Lung Cancer, Protection Against
Interventions: Curcumin C3 complex®, Lovaza®, Placebo; Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 55 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Lisdexamfetamine, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Irritable Bowel Syndrome
Interventions: Mesalamine, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Trauma
Interventions: Propranolol, Propranolol ER, Sugar pills; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cystic Fibrosis
Interventions: Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks), Placebo; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Renal Dialysis, Vitamin D Deficiency
Interventions: Cholecalciferol (Vitamin D); Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 89 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Contraception
Interventions: Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 29 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 24
States / cities: Tucson, Arizona • La Mesa, California • San Diego, California + 8 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Sertraline, Levetiracetam, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Insulin Sensitivity, Obesity
Interventions: Cold exposure, Cold exposure plus propranolol, Thermoneutral Conditions, Cold water consumption, Tepid water consumption, Exercise, Meal consumption; Other
Lead sponsor: Rutgers University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Acute Decompensated Heart Failure
Interventions: Experimental: Placebo, Experimental: Metolazone; Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Canton, Ohio

Search by objective public record fields.

A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure

Dose Range Finding Study of Fedovapagon in Men With Nocturia

Probiotic (Visbiome) for Gulf War Illness

Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia

Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

Remediation of Impaired Self-Regulation in Patients With Mild TBI

Papaya Study ID:20140628

Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder

The Role of Sirolimus in Preventing Functional Decline in Older Adults

RESTOR: PK/PD mTORi Inhibition in Older Adults

Effect of Thiazolidinediones on Human Bone

Duloxetine for Perimenopausal Depression

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

TRAUMA HELP: Healing and Analgesia With Propranolol

Blood Flow and Vascular Function in Cystic Fibrosis

Vitamin D Supplementation in Kidney Disease

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder

The Effect of Brown Adipose Tissue Activation on Insulin Sensitivity in Humans

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.